DKK1 and plasma cell myeloma: These experimental data are supported by clinical studies in patients with multiple myeloma, where myeloma cells secrete DKK1 leading to lytic bone lesions by blocking osteoblast differentiation and enhancing receptor activator of nuclear factor–kappa–B ligand (RANKL)–dependent bone resorption in patients with high disease activity [32].